Reducing Hereditary Cancer Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Reducing Hereditary Cancer Act (H.R. 1526) was a House bill introduced in the 118th Congress aimed at addressing hereditary cancer. Specific provisions, objectives, and mechanisms of the bill are not available in the provided data. The bill was referred to the Subcommittee on Health but ultimately failed or expired without further legislative action.
H.R. 1526 sought to address hereditary cancer issues but did not advance beyond subcommittee referral and expired without enactment.
- The bill was introduced in the House during the 118th Congress.
- It was referred to the Subcommittee on Health on December 17, 2024.
- The bill did not progress further and is listed as failed or expired.
['Individuals at risk of hereditary cancers', 'Healthcare providers specializing in cancer prevention and treatment', 'Public health agencies focused on cancer control']
['Lack of detailed information on bill provisions limits assessment of implementation challenges.', 'No available data on funding mechanisms or enforcement provisions.', "Oversight and authority structures related to the bill's measures are unspecified."]
The bill was introduced in the House and referred to the Subcommittee on Health during the 118th Congress. It did not advance beyond this stage and is recorded as failed or expired. No further legislative actions or debates are documented in the provided data.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased awareness and screening for hereditary cancers if provisions were enacted.', 'Possible impacts on healthcare resource allocation related to cancer prevention and genetic counseling.', "Influence on future legislative efforts addressing hereditary cancer due to the bill's failure."]
The absence of the full bill text and official summary restricts transparency and comprehensive public understanding. The bill's failure to progress beyond subcommittee referral suggests limited legislative momentum. Monitoring similar future bills may provide better insight into policy developments in hereditary cancer.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.